Sanofi Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001121404

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q3 2026 Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024

Q3 2026 · 16 positions · Total reported value $629.87M · Top-10 concentration 92.1% · Updated 2026-11-05

Last updated: 2026-11-05 · Source: SEC EDGAR Form 13F-HR

Turnover: 37.5% · 6 new · 0 cut · 0 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -5.4% · vs SPY -7.6% · Prev Value $534.04M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -10.9% · vs SPY -13.1% · Latest Value $629.87M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, Sanofi disclosed 16 equity positions with a combined reported value of $629.87M. The filing implies a focused portfolio: its ten largest positions account for 92.1% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were MGTX ($134.18M), INBX ($115.89M), NVAX ($74.38M). By sector, the heaviest allocations are Health Care 95.6%, Other 4.4%. Versus the prior quarter, allocation shifted toward Other (+4.4pp) and away from Health Care (-4.4pp).

Versus the prior quarter, Sanofi opened 6 new positions, trimmed 0 and fully exited 0, a turnover rate of 37.5% of positions. The portfolio's overlap with the prior quarter was 62% of names.

The largest new positions opened in Q3 2026 were ANIX ($63.81M), GRTX ($27.70M), ATOS ($18.56M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • ANIX Korsana Biosciences · $63.81M
  • GRTX Electra Therapeutics Inc · $27.70M
  • ATOS Atossa Therapeutics Inc Ordinary Shares · $18.56M
  • ARTV ARTIVA BIOTHERAPEUTICS INC · $11.24M
  • SYRE SPYRE THERAPEUTICS INC · $9.20M
  • SABS SAB BIOTHERAPEUTICS INC · $6.97M

Fully Exited (vs previous quarter)

No tracked position was fully exited this quarter.

Insider Transactions (Form 4)

Latest Sanofi buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-08-10 Conversion Latigo Biotherapeutics, Inc. 177,978 — SEC filing
2026-08-10 Conversion Latigo Biotherapeutics, Inc. 494,800 — SEC filing
2026-08-06 Buy Attovia Therapeutics, Inc. 300,000 $17.00 SEC filing
2026-08-06 Conversion Attovia Therapeutics, Inc. 782,855 — SEC filing

All insider transactions →

Fund Profile

Sanofi is an SEC-registered 13F filer. As of Q2 2026 it reported 10 US equity positions with a combined value of $534.04M. HoldingsHub carries 7 quarters of its filings (Q4 2024–Q2 2026).

Portfolio Structure

  • 10 positions · $534.04M reported value (Q2 2026)
  • Top 10 holdings = 100.0% of reported value
  • Largest position: MGTX (MEIRAGTX HLDGS PLC COM) at 30.9%
  • Average position size: $53.40M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 2 new, 1 exited
  • 8 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: The fund is cautiously bullish on biotech/healthcare, focusing on clinical-stage companies with new positions in gene therapy (MGTX), targeted therapies (ANIX, GRTX), and novel modalities (ATOS), while maintaining stable holdings in established players (NVAX, INBX). 2. Key moves: Added 3 new biotech stocks (ANIX, GRTX, ATOS) totaling ~$74M (11.7% of portfolio); no reductions or sales, indicating conviction in new additions. 3. Portfolio structure: Active, high-conviction healthcare/biotech sector bias (100% holdings), concentrated in small/mid-cap biotechs (avg. market cap <$5B), with high risk appetite due to clinical-stage pipeline exposure. 4. Per-holding one-liner: - MGTX: Gene therapy developer (unverified). - INBX: Oncology-focused biotech (unverified). - NVAX: Vaccine developer (COVID-19). - ANIX: Korsana Biosciences (neuroscience? unverified). - ODTX: Odyssey Therapeutics (kinase inhibitors? unverified). - ANAB: ANAPTYSBIO (immunology? unverified). - AGMB: Agomab (inflammation? unverified). - TRAX: First Tracks Bio (cell therapy? unverified). - GRTX: Electra Therapeutics (epigenetics? unverified). - ATOS: Attovia Therapeutics (protein degradation? unverified). 5. Style summary: Biotech-focused fund with selective, high-conviction additions in clinical-stage therapeutics, maintaining stable core positions.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 95.6%
Other 4.4%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 12.20M $134.18M 21.30%
21.30%
Hold
2 1.16M $115.89M 18.40%
18.40%
Hold
3 6.88M $74.38M 11.81%
11.81%
Hold
4 1.99M $63.81M 10.13%
10.13%
New
5 1.99M $44.22M 7.02%
7.02%
Hold
6 821.92K $41.31M 6.56%
6.56%
Hold
7 2.78M $30.89M 4.91%
4.91%
Hold
8 821.92K $29.13M 4.62%
4.62%
Hold
9 2.46M $27.70M 4.40%
4.40%
New
10 1.08M $18.56M 2.95%
2.95%
New
11 672.78K $11.24M 1.78%
1.78%
New
12 2.71M $11.09M 1.76%
1.76%
Hold
13 912.04K $9.29M 1.48%
1.48%
Hold
14 500.00K $9.20M 1.46%
1.46%
New
15 2.20M $6.97M 1.11%
1.11%
New
16 244.08K $2.02M 0.32%
0.32%
Hold

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q4) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q3)

P 70% R 70% F1 70% (modelled on 2026-Q2; 7/10 hit)

Historical Backtest (6 quarters)

Avg precision 86% · recall 84% · F1 85% · avg rank error 1.5 · Top-10 turnover 12%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2025-Q2 100% 90% 95% MGTX · NVAX · INBX · ANAB · ELDN · LVTX · IGMS · QTTB · INZY MGTX · NVAX · ANAB · INBX · OMDA · LVTX · ELDN · INZY · IGMS · QTTB
2025-Q3 80% 89% 84% MGTX · NVAX · ANAB · INBX · OMDA · LVTX · ELDN · INZY · IGMS · QTTB MGTX · NVAX · INBX · ANAB · IMRX · OMDA · LVTX · ELDN · QTTB
2025-Q4 78% 88% 82% MGTX · NVAX · INBX · ANAB · IMRX · OMDA · LVTX · ELDN · QTTB MGTX · INBX · NVAX · ANAB · IMRX · MPLT · ELDN · QTTB
2026-Q1 100% 89% 94% MGTX · INBX · NVAX · ANAB · IMRX · MPLT · ELDN · QTTB MGTX · INBX · NVAX · ANAB · AGMB · MPLT · IMRX · ELDN · QTTB
2026-Q2 89% 80% 84% MGTX · INBX · NVAX · ANAB · AGMB · MPLT · IMRX · ELDN · QTTB MGTX · INBX · NVAX · ANAB · ODTX · AGMB · MPLT · TRAX · IMRX · QTTB
2026-Q3 ★ 70% 70% 70% MGTX · INBX · NVAX · ANAB · ODTX · AGMB · MPLT · TRAX · IMRX · QTTB MGTX · INBX · NVAX · ANIX · ODTX · ANAB · AGMB · TRAX · GRTX · ATOS

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

FAQ

What did Sanofi buy in 2026-Q3?

In its 2026-Q3 13F filing, Sanofi reported 16 equity positions worth $629.87M in aggregate; its largest disclosed positions were MGTX ($134.18M), INBX ($115.89M), NVAX ($74.38M).

How large is Sanofi's portfolio?

Sanofi reported $629.87M of long equity holdings across 16 positions as of 2026-Q3. Top-10 holdings account for 92.1% of reported value.

What is Sanofi's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/sanofi/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →